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Abstract
Background:  Multiple Myeloma is a cancer of B plasma cells, which produce non-specific
antibodies and proliferate uncontrolled. Due to the potential relapse and non-specificity of current
treatments, immunotherapy promises to be more specific and may induce long-term immunity in
patients. The pituitary tumor transforming gene 1 (PTTG-1) has been shown to be a novel
oncogene, expressed in the testis, thymus, colon, lung and placenta (undetectable in most other
tissues). Furthermore, it is over expressed in many tumors such as the pituitary adenoma, breast,
gastrointestinal cancers, leukemia, lymphoma, and lung cancer and it seems to be associated with
tumorigenesis, angiogenesis and cancer progression. The purpose was to investigate the presence/
rate of expression of PTTG-1 in multiple myeloma patients.
Methods: We analyzed the PTTG-1 expression at the transcriptional and the protein level, by
PCR, immunocytochemical methods, Dot-blot and ELISA performed on patient's sera in 19
multiple myeloma patients, 6 different multiple myeloma cell lines and in normal human tissue.
Results: We did not find PTTG-1 presence in the normal human tissue panel, but PTTG-1 mRNA
was detectable in 12 of the 19 patients, giving evidence of a 63% rate of expression (data confirmed
by ELISA). Four of the 6 investigated cell lines (66.6%) were positive for PTTG-1. Investigations of
protein expression gave evidence of 26.3% cytoplasmic expression and 16% surface expression in
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the plasma cells of multiple myeloma patients. Protein presence was also confirmed by Dot-blot in
both cell lines and patients.
Conclusion: We established PTTG-1's presence at both the transcriptional and protein levels.
These data suggest that PTTG-1 is aberrantly expressed in multiple myeloma plasma cells, is highly
immunogenic and is a suitable target for immunotherapy of multiple myeloma.
Background
Multiple myeloma (MM) is a malignancy of B plasma
cells (PCs). They accumulate in the bone marrow (BM)
causing bone destruction, BM failure [1] and interfere
with the normal PC activity by generating an abnormal,
non-functional and non-specific immunoglobulin (M
protein) [2]. Further, the malignant plasma cells can also
be found in extra-medullary locations, such as peripheral
blood, pleural effusion and ascites [3]. Every year about
15,000 new cases of MM are diagnosed in the U.S. [1]. The
median age of diagnosis is 67 years (it rarely occurs before
age 45) and the median survival is 3 to 4 years [4]. MM
onset is still not understood and since relapses are system-
atically observed after transient complete remission, it
remains an incurable hematological disease [5]. Treat-
ment for MM is currently based on high doses of chemo-
therapy, radiotherapy and autologous stem cell rescue,
but death is the ultimate outcome.
Since the identification of tumor-associated antigens
(TAA), capable of inducing an immune response in cancer
patients, has become a formidable task for tumor immu-
nologists [6], the research of new possible target candi-
dates holds high promise for the success of biological
therapy [7,8]. In fact, the immune system is capable of dis-
criminating between benign and malignant cells by recog-
nizing aberrantly expressed proteins/peptides exposed on
the cell surface in the context of the major histocompati-
bility complex (MHC) [9]. Immune responses are also
highly dependant on the tumor's micro-environment
[10]. It has been shown that the addition of systemic
Interleukin-2 (IL-2) therapy to tumor immunization plays
a pivotal role in increasing the frequency of immune can-
cer rejections [10]. The identification of novel TAA is only
the first step in improving the complementary use of two
biotherapic approaches (active immunization/adoptive
transfer of tumor antigen-specific T cells) and to better
design future simple and safe clinical studies [11].
In the last decade, PTTG-1 has been shown to be a novel
oncogene [12]. Human PTTG-1 is located on chromo-
some 5 and encodes a protein of 202 amino acids (22
kDa) [13]. PTTG-1 is involved in transcriptional and cell
cycle regulation with expression in the normal testis and
thymus, and weak expression signals in colon, small intes-
tine, brain, placenta, and pancreas [12]. Further investiga-
tions showed PTTG-1 to be highly expressed in different
tumor cell lines (promyelocytic leukemia cell line HL-60,
HeLa cell S3, chronic myelogenous leukemia cell line K-
562, lymphoblastic leukemia cell line MOLT-4, Burkitt's
lymphoma cell line Raji, colorectal adenocarcinoma cell
line SW480, lung carcinoma cell A549, melanoma cell
G361) [12]. PTTG-1 has also been shown to be tumori-
genic in vivo [14] and, it seems to be associated with tum-
origenesis, angiogenesis and cancer progression [12]. In
tumorigenesis, PTTG-1 might be playing a dual role. First,
over-expression of PTTG-1 initiates genetic instability
and, second, high PTTG-1 expression induces the trans-
duction of fibroblast growth factor 2 (FGF-2), vascular
endothelial growth factor (VEGF) and other pro-ang-
iogenic genes [15]. Investigated in tumors, PTTG-1 has
been found over expressed in pituitary tumors, thyroid
cancer [16,17], esophageal squamous cancer [18,19],
uterine leioma [20], lung cancer [21,22], lymphoid cancer
[23,24], colon cancer [25], gastric carcinoma [26] testicu-
lar cancer [27], breast cancer [28], astrocytoma cancer
[29,30].
Recently PTTG-1 was investigated in MM and found to be
expressed at the transcriptional level [31]. We wanted to
further investigate MM cases evaluating both the mRNA
and the protein level, comparing our results to a human
normal tissue panel in order to give room to the hypothe-
sis of using PTTG-1 as a target for biological therapy in
MM.
Methods
Patients and materials
We evaluated human normal tissues by means of a nor-
mal tissue panel (Applied Biosystems, Foster City, CA,
USA) and a normal tissue panel array (Pantomics, San
Francisco, CA, USA) prepared for brain, breast, colon,
heart, kidney, liver, lung, ovary, pancreas, skeletal muscle,
spleen, stomach, trachea and bone marrow. Plasma cells
of 19 MM patients (purified by BB4 antibody) and 6
established MM cell lines (KMS11, 8226, ARK-B, ARP-1,
U266, OPM2) were investigated. All of the clinical mate-
rials were obtained with the patient consent and approval
from the local ethics committee. PTTG-1 expression was
evaluated by Reverse Transcription-Polymerase Chain
Reaction (RT-PCR), immunohisto/cytochemistry (IHC/
ICC), immunofluorescence (IF) and fluorescence acti-
vated cell sorter (FACS).Journal of Translational Medicine 2008, 6:15 http://www.translational-medicine.com/content/6/1/15
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RT-PCR
PCR analysis has been performed as previously described
[32,33]. Briefly, 1 µg of total RNA extracted from cells by
Tri-reagent (Sigma, St Louis, MO, USA) was DNAse I
digested (Ambion, Austin, TX, USA) and reverse-tran-
scribed by random hexamers. The primers sequences were
as follows: 5'-GGT TTA AAC CAG GAG TGC CGC-3' and
5'-AAT TCA ACA TCC AGG GTC GAC AG-3' (35 cycles,
annealing 55°C). RNA integrity in each sample was
checked on β-actin gene expression. All results were con-
firmed in 3 independent RT-PCRs.
Immunohistochemistry
Experiments were performed as previously described [33].
We used anti-PTTG-1 (Zymed Laboratories, San Francisco,
CA, USA) as primary antibody at a dilution factor of 1:100
(diluted in PBS 1× + BSA 0.1%). The DAKO HRP-labeled
Envision system was used as secondary antibody (DAKO,
Carpinteria, CA, USA), followed by 5 minutes dark incu-
bation with DAB system (DAKO), used to yield brown
reaction products. Cells were counter-stained with hema-
toxylin (Fisher Scientific, Pittsburg, PA, USA) and results
were evaluated by light microscope (Leica DMLA, USA).
Pictures were taken at 20×, 40× and 63× ranges of magni-
tude and analyzed by Isole software.
Immunocytochemistry/Immunofluorescence
Experiments were performed as previously described [33].
MM plasma cells and cell lines were spun in a cytospin
column (5 × 104 cells/slide), fixed with SlideRite (Fisher,
USA) and air-dried overnight. Each sample was either per-
meabilized (P) in PBS1X/0.1% Triton X-100 for 15 min-
utes at 4°C or not permeabilized (NP). For ICC, cells were
treated with anti-PTTG-1 primary antibody (Zymed Lab)
(1:100 dilution), incubated for 30 minutes with the Envi-
sion System (DAKO) and 5 minutes with DAB (DAKO).
The ICC reaction was observed by light microscope
(Leica). For IF, cells were incubated overnight in a wet
chamber at 4°C with anti-PTTG-1 primary antibody
(Zymed Lab) (1:100 dilution), then with FITC conjugated
IgG secondary antibodies (1:500, Abcam, USA). Results
were analyzed using an Olympus IX71 inverted micro-
scope equipped with a Fluoview 300 confocal laser sys-
tem.
Protein generation
PTTG-1 protein was generated through the use of PQE30
plasmid (Fig. 1A) transformed into M15 E. coli cells. This
plasmid contains ampicillin resistance gene and 6× His-
tag. IPTG (1 µM) was added as a promoter inducer once
the cultures were grown and an O.D. of 0.6 was reached.
Following growth of the E. coli cells, Qiagen Ni-NTA Fast
Start Kit was used from the cell lysis step till the purifica-
tion step by the nickel columns provided in the kit. SDS-
PAGE (10%) analysis confirmed the purification of the
PTTG-1 (final concentration 5 mg/ml) protein (Fig. 1B).
Enzyme-linked immunosorbent assay
An enzyme-linked immunosorbent assay (ELISA) was
performed [33] on the sera of 19 MM patients and 11
healthy donors with no known abnormalities. Polysty-
rene 96-well flat-bottom plates were coated with PTTG-1
recombinant protein (5 µg/µl) and incubated overnight at
4°C. After washing and blocking with SuperBlock® buffer
(Pierce, Rockford, IL, USA), plates were placed at 37°C for
2 hours. Each sample, as well as the negative controls
(PBS/FBS 1×) was diluted 1:1000 in SuperBlock® buffer
and incubated for 4 hours at RT. After washing with PBS/
Tween20 0.05%, horseradish peroxidase conjugated goat
anti-human IgG (Pierce), diluted 1:5000 in SuperBlock®,
was added and allowed to incubate at RT for 2 hours.
Then 1-Step Ultra TMB-ELISA chromogenic substrate
(Pierce) was added to each well for color development for
1A. Scheme of pQE30 plasmid for the generation of PTTG-1  protein Figure 1
1A. Scheme of pQE30 plasmid for the generation of 
PTTG-1 protein.1B. SDS-PAGE gel for purification of 
PTTG-1 protein stained with commassie blue. Line 1) wash-
ing buffer, 2) flow through fraction, 3) elution 2, 4) elution 1, 
5) pQE30/pttg-1 with IPTG, 6) pQE30/pttg-1 without IPTG, 
7) Marker.
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10 minutes. After blocking the reaction with sulfuric acid,
the intensity was measured by Victor 2 micro plate multi-
label counter (PerkinElmer, Waltham, MA, USA) at 450
nm. All samples were run in triplicates.
Dot-blot
The presence of PTTG-1 protein was also evaluated by
Dot-blot. Cell lysates of 5 MM cell lines and 19 MM
patients were blotted on a nitrocellulose membrane by
vacuum aspiration in a Bio-Dot Apparatus (Bio-Rad Lab-
oratories). The membrane dried at room temperature for
30 minutes and then blocked for 45 minutes in milk 5%
and TBST (Tris 100 mM, NaCl 1.5 M, Tween20 0.05%).
Membrane was washed in TBST 2 times and incubated for
1 h with the primary antibody (Zymed Lab) diluted 1:250.
After 2 washes of 5 minutes in TBST, membrane was incu-
bated for 1 hour with secondary antibody (ImmunoPure,
PIERCE) diluted 1:5000. Immuno-revelation was per-
formed incubating the membrane with Opti-4CN and
Amplified Opti-4CN Kit (Bio-Rad Laboratories) for 15
min. All the samples were run in three different dilutions
in TBS 1× (1:100, 1:5000, and 1:1000).
FACS
The expression of PTTG-1 has been demonstrated by
FACS analysis as previously described with a double stain
reaction [32]. Briefly MM plasma cells and MM cell lines
were incubated with anti-PTTG-1 primary antibody
(Zymed Lab) diluted in PBS 1×. PBS 1× alone was used as
negative control. PE-conjugated anti-rabbit IgG (Imgenex,
San Diego, CA, USA) was used to detect and bind the pri-
mary antibody. Analysis was performed using a fluores-
cence-activated cell scanner (B&D, Bioscience-
PharMingen, Franklin Lakes, NJ, USA).
Results
We wanted to investigate a panel of normal human tissues
constituted by brain, breast, colon, heart, kidney, liver,
lung, ovary, pancreas, skeletal muscle, spleen, stomach
and bone marrow to evaluate the presence of PTTG-1 at
both the transcriptional and the protein levels. Our inves-
tigation of the 13 above mentioned human normal tissues
gave no evidence of positive band signals for PTTG-1 (Fig.
2A) by PCR. Also, the human normal tissue array, investi-
gated by IHC, did not show positive staining (Fig. 2B), as
expected and suggested by the PCR data.
The evaluation of the plasma cells of 19 MM bearing
patients gave evidence of 12 positive cases (Fig. 3Ai),
showing a 63% expression rate. The further evaluation of
6 MM established cell lines, by PCR, showed 4 positive
cases (67%): KMS-11, 8226, ARK-B and ARP-1 (Fig. 3Bi).
We further investigated the MM plasma cells and the MM
cell lines for the protein expression of PTTG-1. We wanted
to specifically evaluate if PTTG-1 is expressed or shown at
both the cytoplasmic and/or surface levels. Permeabilized
and non-permeabilized cells were treated either by ICC or
IF, and analyzed by microscope and further evaluated by
FACS. The cytoplasmic expression of PTTG-1 was found in
five of the 19 patients (26.3%), while the surface staining
was detectable in three of the 19 patients (16%). Repre-
sentative cases of cytoplasmic and surface protein expres-
sion are shown in Fig. 3Aii. In the MM cell lines, we found
cytoplasmic staining only within the 4 positive MM cell
lines, as shown in the representative case of the 8226 cell
line (Fig. 3Bii). Protein presence was also confirmed by
Dot-blot analysis, performed on MM cell lines lysates and
patients sera (Fig. 4A).
To determine immunogenicity we investigated the pres-
ence of IgG antibodies against PTTG-1 in the serum of the
19 MM patients by ELISA (Fig. 4B). A positive signal was
shown in 12/19 of the analyzed cases (63%). The cut-off
point (mean + 3 STDEV), determined on the healthy con-
trols, was significantly low with an OD450 nm = 0.4041,
while negative controls had an OD425 nm = 0.044.
Discussion
We report for the first time the interesting finding that
PTTG-1 is aberrantly expressed in MM at both the tran-
scriptional and the protein levels. Our investigations gave
evidence of its presence, at the transcriptional level, in
63% of the analyzed cases. In our data, it was shown that
PTTG-1 was not detectable at the mRNA or protein levels
in human normal tissue panels, while other reports
showed PTTG-1 to be weakly expressed in normal colon,
lung, thymus, and placenta [12]. Since PTTG-1 has been
described as an oncogene involved in tumorigenesis, its
aberrant expression in MM may play a significant role in
the onset and development of the disease.
A previous study investigated the presence of PTTG-1 in a
pool of MM patients showing a significant over-expres-
sion of the gene at the transcriptional level [31]. Starting
from this observation, and considering PTTG-1 as associ-
ated with MM, we wanted to extend the scenario analyz-
ing the expression of PTTG-1 in MM PCs, specifically at
the protein level.
Our data shows that PTTG-1 is present at the protein level
both in the cytoplasmic district and, interestingly, on the
surface of MM PCs. This is relevant because most of the
tumor-associated antigens (TAAs) are not expressed on
the surface of tumor cells, shadowing their usefulness as
reliable targets, able to elicit an effective response of the
host immune system [34].
ELISA results showed that PTTG-1 is immunogenic since
anti-PTTG-1 IgG antibodies were found in 12/19 patients
(63%). We suggest to conduct further studies in order toJournal of Translational Medicine 2008, 6:15 http://www.translational-medicine.com/content/6/1/15
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examine the machinery and the mechanisms involved in
the protein's expression on the surface of MM PCs.
In fact, it has been shown that, in tumors, some proteins
are present either in their native form or in a modified
form (due to a mutation in the gene or to post-transla-
tional modifications) [34]. Modified and aberrantly
expressed proteins can be processed in the tumor cell (by
the proteasome) where they are reduced into small pep-
tides of 8–15 AA [35] and then they are bound to MHC
class I molecules in the endoplasmic reticulum [34]. The
processed epitope is transported to the cell surface where
it can induce an immune response of host CD8+ CTLs
[34,36]. In order to improve the specificity of antigen spe-
cific-CTL, there is ongoing research (based on algorithms)
of highly immunogenic epitopes within TAAs [37].
Emphasis should also be placed on increasing our knowl-
edge of cancer immunobiology, as well as on the improve-
ment of cellular immune function monitoring, after
vaccination [38]. Obstacles to effective translational med-
icine still remain [39]. For example, both the challenge of
translating basic science discoveries into clinical studies
and the translation of clinical studies into medical prac-
tice should be stressed [39]. In fact, high morbidity and
mortality are attributable to limited current therapies;
there is a need for a new generation of vaccines that are
cost effective, safe and able to induce durable immune
responses [40].
PTTG-1 has been described, in normal conditions, as a
transcriptional factor, mainly expressed in the nuclei of
cells. This gives room to the hypothesis that PTTG-1 may
be expressed, in tumors, in a mutated form either acquir-
ing a trans-membrane domain or getting processed by the
2A. The PCR results of the normal tissue panel are shown Figure 2
2A. The PCR results of the normal tissue panel are shown. Except for the positive control (the testis), none of the ana-
lyzed organs showed positive band signals. 2B. IHC results did not show the presence of PTTG-1 at the protein level in the 
normal tissue array. Investigated tissues: 1) brain, 2) breast, 3) colon, 4) heart, 5) kidney, 6) liver, 7) lung, 8) ovary, 9) pancreas, 
10) skeletal muscle, 11) spleen, 12) stomach and 13) bone marrow.
uuuuuuuuuu
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above described machinery system. Nevertheless, in the
case of modified, aberrantly expressed proteins, it is rele-
vant to consider that post-translational modifications of
the antigen may limit the cloning of effective CTLs. In fact
these modifications need to be taken in consideration in
order to clone highly specific CTLs and to improve the
effectiveness of a CTL based biological therapy [34].
Conclusion
Our findings suggest that PTTG-1 is a potential suitable
target in MM. Even if further studies are needed to support
this suggestion, there is a high probability that PTTG-1 is
part of the rising group of new targets in MM whose dis-
covery gives hope for the development, in the near future,
of a successful treatment for MM, based on a polyvalent
vaccine strategy [7].
3A. i. The PCR result shows 12/19 positive cases for PTTG-1 at the transcriptional level Figure 3
3A. i. The PCR result shows 12/19 positive cases for PTTG-1 at the transcriptional level.ii. Representative cases of 
patient MM plasma cells. In the (P) panel, the cytoplasmic staining is shown by ICC, IF and FACS. Also the NP panel shows a 
positive result for surface staining by ICC, IF and FACS methods. 3B. i. The investigation of the 6 established MM cell lines 
gave positive band signals in the four cases of KMS-11, 8226, ARK-B and ARP-1. ii. The evaluation of PTTG-1 protein expres-
sion showed only cytoplasmic but not surface positive reaction. The case of the permeabilized (P) and not permeabilized (NP) 
8226 cell line is shown by means of ICC, IF and FACS.Journal of Translational Medicine 2008, 6:15 http://www.translational-medicine.com/content/6/1/15
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